Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 4
2014 5
2015 11
2016 5
2017 6
2018 8
2019 11
2020 10
2021 17
2022 11
Text availability
Article attribute
Article type
Publication date

Search Results

75 results
Results by year
Filters applied: . Clear all
Page 1
Use of oclacitinib as antipruritic drug during sarcoptic mange infestation treatment.
Cornegliani L, Guidi E, Vercelli A. Cornegliani L, et al. Vet Dermatol. 2020 Dec;31(6):505. doi: 10.1111/vde.12920. Vet Dermatol. 2020. PMID: 33226173
The aim of this retrospective study was to evaluate efficacy of oclacitinib in alleviating pruritus and inflammation in dogs affected by scabies. ...All dogs were treated at day (D)0 with systemic antiparasitic drugs (e.g. moxidectin, sarolaner, afoxolaner) in association …
The aim of this retrospective study was to evaluate efficacy of oclacitinib in alleviating pruritus and inflammation in dogs affected …
A pharmacokinetic study of oclacitinib maleate in six cats.
Ferrer L, Carrasco I, Cristòfol C, Puigdemont A. Ferrer L, et al. Vet Dermatol. 2020 Apr;31(2):134-137. doi: 10.1111/vde.12819. Epub 2019 Nov 26. Vet Dermatol. 2020. PMID: 31769185
BACKGROUND: Oclacitinib is a Janus kinase (JK)1 inhibitor that has been shown to be effective and safe for the treatment of allergic dermatitis in dogs. ...OBJECTIVE: To determine the pharmacokinetic parameters of oclacitinib in cats after oral and intravenous admin …
BACKGROUND: Oclacitinib is a Janus kinase (JK)1 inhibitor that has been shown to be effective and safe for the treatment of allergic …
Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response.
Carrasco I, Ferrer L, Puigdemont A. Carrasco I, et al. J Feline Med Surg. 2021 Oct 6:1098612X211048458. doi: 10.1177/1098612X211048458. Online ahead of print. J Feline Med Surg. 2021. PMID: 34612749
Oclacitinib concentrations showed no correlation with clinical effects (SCORFAD and PVAS). CONCLUSIONS AND RELEVANCE: Oclacitinib emerged as being safe and effective to control clinical signs of FASS. ...
Oclacitinib concentrations showed no correlation with clinical effects (SCORFAD and PVAS). CONCLUSIONS AND RELEVANCE: Oclacitinib
Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation and cytokine production.
Banovic F, Tarigo J, Gordon H, Barber JP, Gogal RM Jr. Banovic F, et al. Vet Dermatol. 2019 Feb;30(1):17-e6. doi: 10.1111/vde.12698. Epub 2018 Nov 12. Vet Dermatol. 2019. PMID: 30417482
METHODS AND MATERIALS: Lymphocyte-enriched cells were incubated with or without the T-cell mitogen concanavalin A (Con A), oclacitinib (0.5, 1 or 10 muM), ciclosporin (200 ng/mL), Con A + oclacitinib 1 muM and Con A + ciclosporin. We assessed both T-cell proliferati …
METHODS AND MATERIALS: Lymphocyte-enriched cells were incubated with or without the T-cell mitogen concanavalin A (Con A), oclacitinib
The role of oclacitinib in the management of ischaemic dermatopathy in four dogs.
Levy BJ, Linder KE, Olivry T. Levy BJ, et al. Vet Dermatol. 2019 Jun;30(3):201-e63. doi: 10.1111/vde.12743. Epub 2019 Apr 21. Vet Dermatol. 2019. PMID: 31006925
Remission was maintained in two dogs with lower doses or dosing frequencies of oclacitinib, whereas the two others required persistent twice daily administration of this JAKinib. ...Such observation warrants further studies of the safety, efficacy and mechanism of action o …
Remission was maintained in two dogs with lower doses or dosing frequencies of oclacitinib, whereas the two others required persisten …
Comparative efficacy of topical oclacitinib 0.1% and tacrolimus 0.01% in canine keratoconjunctivitis sicca.
de Oliveira JK, Williams DL, Bollmann C, de Seabra NM, Bortolini M, Montiani-Ferreira F. de Oliveira JK, et al. Vet Ophthalmol. 2019 Sep;22(5):633-643. doi: 10.1111/vop.12634. Epub 2019 Feb 6. Vet Ophthalmol. 2019. PMID: 30724448
PROCEDURES: The animals were submitted to a randomized, open-label, 5-week study and divided into 3 treatment groups treated with the following ophthalmic solutions: (a) 0.1% oclacitinib, (b) 0.1% oclacitinib +0.01% tacrolimus, and (c) 0.01% tacrolimus. ...Synergism …
PROCEDURES: The animals were submitted to a randomized, open-label, 5-week study and divided into 3 treatment groups treated with the follow …
Oclacitinib, a Janus Kinase Inhibitor, Reduces the Frequency of IL-4- and IL-10-, but Not IFN-γ-, Producing Murine CD4+ and CD8+ T Cells and Counteracts the Induction of Type 1 Regulatory T Cells.
Jasiecka-Mikołajczyk A, Jaroszewski JJ, Maślanka T. Jasiecka-Mikołajczyk A, et al. Molecules. 2021 Sep 17;26(18):5655. doi: 10.3390/molecules26185655. Molecules. 2021. PMID: 34577127 Free PMC article.
The purpose of the present study was to broaden the knowledge and understanding of the effects of oclacitinib (OCL), a Janus kinase inhibitor, on T cells in the context of both the immune mechanisms underlying anti-inflammatory and anti-allergic properties of the drug and …
The purpose of the present study was to broaden the knowledge and understanding of the effects of oclacitinib (OCL), a Janus kinase i …
Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus.
Carrasco I, Martínez M, Albinyana G. Carrasco I, et al. Vet Dermatol. 2021 Jun;32(3):299-301. doi: 10.1111/vde.12949. Epub 2021 Mar 15. Vet Dermatol. 2021. PMID: 33720467
This report describes one case of feline PF successfully controlled using oral oclacitinib, suggesting a possible therapeutic alternative to glucocorticoids in some cases....
This report describes one case of feline PF successfully controlled using oral oclacitinib, suggesting a possible therapeutic alterna …
A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats.
Lopes NL, Campos DR, Machado MA, Alves MSR, de Souza MSG, da Veiga CCP, Merlo A, Scott FB, Fernandes JI. Lopes NL, et al. BMC Vet Res. 2019 May 8;15(1):137. doi: 10.1186/s12917-019-1893-x. BMC Vet Res. 2019. PMID: 31068210 Free PMC article.
Studies available in cats are very limited and as there is a potential role for oclacitinib in the control of pruritus in this specie, the aim of this study was to evaluate the safety and clinical effects of oral oclacitinib maleate in healthy cats. ...Oclacitini
Studies available in cats are very limited and as there is a potential role for oclacitinib in the control of pruritus in this specie …
75 results